{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T03:51:10Z","timestamp":1774842670676,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Flow cytometry (FC) is a popular method to detect bone marrow (BM) involvement in patients with B-cell non-Hodgkin lymphoma (B-NHL). The majority of screen panels of FC still rely on finding monoclonal B-cells, e.g., B-cells with immunoglobin (Ig) light-chain restriction, which has many limitations. Therefore, exploring new markers is warranted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 52 cases of B-NHL with BM involvement were collected. The median age was 60\u2009years. Out of these 52 cases, 34 were male, and 18 were female. A 10-color FC panel was used to detect the expression of CD54 on lymphoma cells. The expression of CD54 was calculated as the mean fluorescence index ratio (MFIR) and was described as the mean\u2009\u00b1\u2009standard error of the mean (SEM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Up to 18\/52 (34.62%) of BM specimens abnormally expressed an increased level of CD54, including 1\/10 cases of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), 9\/13 cases of mantle cell lymphoma (MCL), 2\/14 cases of follicular lymphoma (FL), 5\/9 cases of marginal zone lymphoma (MZL), and 1\/3 cases of high-grade B-NHL (HG B-NHL). The expression level of CD54 was significantly increased in MCL cases (53.41\u2009\u00b1\u200911.04) compared with CLL\/SLL cases (11.66\u2009\u00b1\u20092.79) and FL cases (13.49\u2009\u00b1\u20092.81). The lowest percentage of CD54-positive B-cells attained 0.13%. In 5\/9 cases of MZL and 1\/3 cases of HG B-NHL, increased expression of CD54 was the only abnormal immunophenotype detected besides Ig light-chain restriction. No aberrant CD54 expression was identified by FC in lymphoplasmacytic lymphoma (LPL) (0\/2) and Burkitt lymphoma (BL) (0\/1) cases. Aberrant expression of CD54 was not related to plasma cell differentiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Lymphoma cells, especially in MCL and MZL cases, frequently show increased expression of CD54. Such aberrant expression is not related to plasma cell differentiation. We highly recommend adding CD54 to the FC screening panel to detect BM involvement in patients with B-NHL.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-021-09061-3","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T06:03:20Z","timestamp":1638943400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens"],"prefix":"10.1186","volume":"21","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haval","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"9061_CR1","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365. https:\/\/doi.org\/10.1182\/blood-2003-12-4434.","journal-title":"Blood."},{"key":"9061_CR2","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361. https:\/\/doi.org\/10.1182\/blood-2006-08-038257.","journal-title":"Blood."},{"key":"9061_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837\u201342. https:\/\/doi.org\/10.1182\/blood-2013-09-524108.","journal-title":"Blood."},{"key":"9061_CR4","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","volume":"130","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. Blood. 2017;130:1409\u201317. https:\/\/doi.org\/10.1182\/blood-2017-03-771915.","journal-title":"Blood"},{"key":"9061_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132:49\u201358. https:\/\/doi.org\/10.1182\/blood-2017-11-816405.","journal-title":"Blood."},{"key":"9061_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1186\/1471-2407-10-644","volume":"10","author":"P Mancuso","year":"2010","unstructured":"Mancuso P, Calleri A, Antoniotti P, Quarna J, Pruneri G, Bertolini F. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer. 2010;10:644. https:\/\/doi.org\/10.1186\/1471-2407-10-644.","journal-title":"BMC Cancer"},{"key":"9061_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1600-0609.2010.01503.x","volume":"85","author":"M Merli","year":"2010","unstructured":"Merli M, Arcaini L, Boveri E, Rattotti S, Picone C, Passamonti F, et al. Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. Eur J Haematol. 2010;85:405\u201315. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01503.x.","journal-title":"Eur J Haematol"},{"key":"9061_CR8","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.3109\/10428194.2013.788697","volume":"54","author":"H Arima","year":"2013","unstructured":"Arima H, Maruoka H, Nasu K, Tabata S, Kurata M, Matsushita A, et al. Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:2645\u201353. https:\/\/doi.org\/10.3109\/10428194.2013.788697.","journal-title":"Leuk Lymphoma"},{"key":"9061_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3343\/alm.2015.35.2.187","volume":"35","author":"B Kim","year":"2015","unstructured":"Kim B, Lee ST, Kim HJ, Kim SH. Bone marrow flow cytometry in staging of patients with B-cell non-Hodgkin lymphoma. Ann Lab Med. 2015;35:187\u201393. https:\/\/doi.org\/10.3343\/alm.2015.35.2.187.","journal-title":"Ann Lab Med"},{"key":"9061_CR10","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1080\/10428194.2019.1587755","volume":"60","author":"U Greenbaum","year":"2019","unstructured":"Greenbaum U, Levi I, Madmoni O, Lior Y, Al-Athamen K, Perry ZH, et al. The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry. Leuk Lymphoma. 2019;60:2477\u201382. https:\/\/doi.org\/10.1080\/10428194.2019.1587755.","journal-title":"Leuk Lymphoma"},{"key":"9061_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/cyto.b.21863","volume":"98","author":"F Martin-Moro","year":"2020","unstructured":"Martin-Moro F, Piris-Villaespesa M, Marquet-Palomanes J, Garcia-Cosio M, Villarrubia J, Lario A, et al. Bone marrow infiltration by flow cytometry at diffuse large B-cell lymphoma NOS diagnosis implies worse prognosis without considering bone marrow histology. Cytometry B Clin Cytom. 2020;98:525\u20138. https:\/\/doi.org\/10.1002\/cyto.b.21863.","journal-title":"Cytometry B Clin Cytom"},{"key":"9061_CR12","doi-asserted-by":"publisher","first-page":"106267","DOI":"10.1016\/j.leukres.2019.106267","volume":"88","author":"T Statuto","year":"2020","unstructured":"Statuto T, Valvano L, Calice G, Villani O, Pietrantuono G, Mansueto G, et al. Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients. Leuk Res. 2020;88:106267. https:\/\/doi.org\/10.1016\/j.leukres.2019.106267.","journal-title":"Leuk Res"},{"key":"9061_CR13","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1182\/blood.V91.6.1864","volume":"91","author":"DW Bahler","year":"1998","unstructured":"Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren's syndrome) begin as nonmalignant antigen-selected expansions. Blood. 1998;91:1864\u201372.","journal-title":"Blood."},{"key":"9061_CR14","doi-asserted-by":"publisher","unstructured":"Saxena A, Moshynska O, Kanthan R, Bhutani M, Maksymiuk AW, Lukie BE. Distinct B-cell clonal bands in helicobacter pylori gastritis with lymphoid hyperplasia. J Pathol. 2000;190:47\u201354. https:\/\/doi.org\/10.1002\/(SICI)1096-9896(200001)190:1<47::AID-PATH506>3.0.CO;2-O.","DOI":"10.1002\/(SICI)1096-9896(200001)190:1<47::AID-PATH506>3.0.CO;2-O"},{"key":"9061_CR15","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood-2004-01-0385","volume":"104","author":"AD Attygalle","year":"2004","unstructured":"Attygalle AD, Liu H, Shirali S, Diss TC, Loddenkemper C, Stein H, et al. Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood. 2004;104:3343\u20138. https:\/\/doi.org\/10.1182\/blood-2004-01-0385.","journal-title":"Blood."},{"key":"9061_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1309\/4EJ8-T3R2-ERKQ-61WH","volume":"121","author":"SJ Kussick","year":"2004","unstructured":"Kussick SJ, Kalnoski M, Braziel RM, Wood BL. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J Clin Pathol. 2004;121:464\u201372. https:\/\/doi.org\/10.1309\/4EJ8-T3R2-ERKQ-61WH.","journal-title":"Am J Clin Pathol"},{"key":"9061_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/leu.2009.287","volume":"24","author":"TD Shanafelt","year":"2010","unstructured":"Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010;24:512\u201320. https:\/\/doi.org\/10.1038\/leu.2009.287.","journal-title":"Leukemia."},{"key":"9061_CR18","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3324\/haematol.2013.085506","volume":"98","author":"RK Pillai","year":"2013","unstructured":"Pillai RK, Surti U, Swerdlow SH. Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. Haematologica. 2013;98:1571\u201380. https:\/\/doi.org\/10.3324\/haematol.2013.085506.","journal-title":"Haematologica."},{"key":"9061_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1309\/28ED-MM0T-DT3B-MT4P","volume":"113","author":"Z Kaleem","year":"2000","unstructured":"Kaleem Z, Zehnbauer BA, White G, Zutter MM. Lack of expression of surface immunoglobulin light chains in B-cell non-Hodgkin lymphomas. Am J Clin Pathol. 2000;113:399\u2013405. https:\/\/doi.org\/10.1309\/28ED-MM0T-DT3B-MT4P.","journal-title":"Am J Clin Pathol"},{"key":"9061_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1309\/57G0-1BNF-KB9R-L4HN","volume":"118","author":"S Li","year":"2002","unstructured":"Li S, Eshleman JR, Borowitz MJ. Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B-cell lymphoma. Am J Clin Pathol. 2002;118:229\u201334. https:\/\/doi.org\/10.1309\/57G0-1BNF-KB9R-L4HN.","journal-title":"Am J Clin Pathol"},{"key":"9061_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00202069","volume":"74","author":"A van de Stolpe","year":"1996","unstructured":"van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med (Berl). 1996;74:13\u201333. https:\/\/doi.org\/10.1007\/BF00202069.","journal-title":"J Mol Med (Berl)"},{"key":"9061_CR22","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.4049\/jimmunol.146.6.1773","volume":"146","author":"P Kuhlman","year":"1991","unstructured":"Kuhlman P, Moy VT, Lollo BA, Brian AA. The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. Contributions of adhesion and co-activation. J Immunol. 1991;146:1773\u201382.","journal-title":"J Immunol"},{"key":"9061_CR23","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1073\/pnas.85.9.3095","volume":"85","author":"AW Boyd","year":"1988","unstructured":"Boyd AW, Wawryk SO, Burns GF, Fecondo JV. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci U S A. 1988;85:3095\u20139. https:\/\/doi.org\/10.1073\/pnas.85.9.3095.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9061_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1084\/jem.167.6.1811","volume":"167","author":"CD Gregory","year":"1988","unstructured":"Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med. 1988;167:1811\u201324. https:\/\/doi.org\/10.1084\/jem.167.6.1811.","journal-title":"J Exp Med"},{"key":"9061_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1186\/s12885-021-08753-0","volume":"21","author":"W Wang","year":"2021","unstructured":"Wang W, Li Y, Rivera Rivera X, Zhao L, Mei D, Hu W, et al. Application of CD54 in diagnosing bone marrow involvement by using flow cytometry in patients with diffuse large B-cell lymphoma. BMC Cancer. 2021;21:1011. https:\/\/doi.org\/10.1186\/s12885-021-08753-0.","journal-title":"BMC Cancer"},{"key":"9061_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood."},{"key":"9061_CR27","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2017","unstructured":"Swerdlow SHCEHN, Jaffe ES, Pileri SA, Stein H, Thiele J, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017."},{"key":"9061_CR28","doi-asserted-by":"publisher","DOI":"10.1201\/9781315113715","volume-title":"Flow Cytometry in neoplastic hematology: morphologic-Immunophenotypic correlation","author":"W Gorczyca","year":"2017","unstructured":"Gorczyca W. Flow Cytometry in neoplastic hematology: morphologic-Immunophenotypic correlation. New York: CRC Press; 2017."},{"key":"9061_CR29","volume-title":"Bone marrow pathology","author":"KRK Foucar","year":"2010","unstructured":"Foucar KRK, Czuchlewski D. Bone marrow pathology. 3rd ed. Chicago: American Society for Clinical Pathology Press; 2010.","edition":"3"},{"key":"9061_CR30","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.4049\/jimmunol.1101230","volume":"187","author":"M Jourdan","year":"2011","unstructured":"Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T, et al. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 2011;187:3931\u201341. https:\/\/doi.org\/10.4049\/jimmunol.1101230.","journal-title":"J Immunol"},{"key":"9061_CR31","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1080\/10428190600709127","volume":"47","author":"B Schmidt","year":"2006","unstructured":"Schmidt B, Kremer M, Gotze K, John K, Peschel C, Hofler H, et al. Bone marrow involvement in follicular lymphoma: comparison of histology and flow cytometry as staging procedures. Leuk Lymphoma. 2006;47:1857\u201362. https:\/\/doi.org\/10.1080\/10428190600709127.","journal-title":"Leuk Lymphoma"},{"key":"9061_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1756-8722-2-49","volume":"2","author":"D Talaulikar","year":"2009","unstructured":"Talaulikar D, Shadbolt B, Dahlstrom JE, McDonald A. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the international prognostic index (IPI). J Hematol Oncol. 2009;2:49. https:\/\/doi.org\/10.1186\/1756-8722-2-49.","journal-title":"J Hematol Oncol"},{"key":"9061_CR33","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJ van Dongen","year":"2012","unstructured":"van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908\u201375. https:\/\/doi.org\/10.1038\/leu.2012.120.","journal-title":"Leukemia."},{"key":"9061_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/cyto.b.21233","volume":"88","author":"A Rajab","year":"2015","unstructured":"Rajab A, Porwit A. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube. Cytometry B Clin Cytom. 2015;88:253\u201360. https:\/\/doi.org\/10.1002\/cyto.b.21233.","journal-title":"Cytometry B Clin Cytom"},{"issue":"Suppl 1","key":"9061_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/ijlh.12678","volume":"39","author":"A Rajab","year":"2017","unstructured":"Rajab A, Axler O, Leung J, Wozniak M, Porwit A. Ten-color 15-antibody flow cytometry panel for immunophenotyping of lymphocyte population. Int J Lab Hematol. 2017;39(Suppl 1):76\u201385. https:\/\/doi.org\/10.1111\/ijlh.12678.","journal-title":"Int J Lab Hematol"},{"key":"9061_CR36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cyto.b.21251","volume":"88","author":"BD Hedley","year":"2015","unstructured":"Hedley BD, Keeney M, Popma J, Chin-Yee I. Novel lymphocyte screening tube using dried monoclonal antibody reagents. Cytometry B Clin Cytom. 2015;88:361\u201370. https:\/\/doi.org\/10.1002\/cyto.b.21251.","journal-title":"Cytometry B Clin Cytom"},{"key":"9061_CR37","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/leu.2015.313","volume":"30","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study. Leukemia. 2016;30:929\u201336. https:\/\/doi.org\/10.1038\/leu.2015.313.","journal-title":"Leukemia."},{"key":"9061_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cyto.b.21210","volume":"88","author":"J Chovancova","year":"2015","unstructured":"Chovancova J, Bernard T, Stehlikova O, Salek D, Janikova A, Mayer J, et al. Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach. Cytometry B Clin Cytom. 2015;88:92\u2013100. https:\/\/doi.org\/10.1002\/cyto.b.21210.","journal-title":"Cytometry B Clin Cytom"},{"key":"9061_CR39","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2015.134957","volume":"101","author":"M Cheminant","year":"2016","unstructured":"Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A, et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica. 2016;101:336\u201345. https:\/\/doi.org\/10.3324\/haematol.2015.134957.","journal-title":"Haematologica."},{"key":"9061_CR40","doi-asserted-by":"publisher","first-page":"100778","DOI":"10.1016\/j.blre.2020.100778","volume":"47","author":"M Sorigue","year":"2021","unstructured":"Sorigue M, Canamero E, Miljkovic MD. Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry. Blood Rev. 2021;47:100778. https:\/\/doi.org\/10.1016\/j.blre.2020.100778.","journal-title":"Blood Rev"},{"key":"9061_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1309\/AJCP0XQDGKFR0HTW","volume":"133","author":"SD Schniederjan","year":"2010","unstructured":"Schniederjan SD, Li S, Saxe DF, Lechowicz MJ, Lee KL, Terry PD, et al. A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. Am J Clin Pathol. 2010;133:718\u201326. https:\/\/doi.org\/10.1309\/AJCP0XQDGKFR0HTW.","journal-title":"Am J Clin Pathol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09061-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09061-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09061-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T16:38:28Z","timestamp":1673973508000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09061-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9061"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09061-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Ethical Committee of the Peking University International Hospital (C2017\u2013006), following the guideline of the Helsinki Declaration of 2008.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We obtained written informed consent from all patients in the study to publish the manuscript reporting data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1315"}}